Mevalonate pathway inhibition affects bladder cancer metastasis

ABSTRACT: Metastasis is an important factor affecting the prognosis and survival of bladder cancer (BLCA) patients. Our previous study found that the mevalonate pathway is associated with the migratory ability of bladder cancer cells, but the exact mechanism is unclear. Here, we found that BLCA patients with mevalonate pathway activation had a poorer prognosis. Inhibition of the mevalonate pathway (simvastatin or zoledronic acid) resulted in a significant decrease in the migratory ability of BLCA cells. Therefore, we used proteomics to detect simvastatin- or zoledronic acid-treated BLCA cells to explore the effect of the mevalonate pathway on key proteins in BLCA cells.

ORGANISM(S): Homo Sapiens

SUBMITTER: Yu Xiao  

PROVIDER: PXD048067 | iProX | Mon Sep 09 00:00:00 BST 2024

REPOSITORIES: iProX